US vs Regenerative Sciences Comes to End

Tweet 

A court case we blogged a fair amount about even before it started (see the first post in 2008) appears to have finally come to an end in the DC Circuit Court's decision to uphold the ruling in favor of the FDA.

United States Court of Appeals 
FOR THE DISTRICT OF COLUMBIA CIRCUIT 

Decided February 4, 2014 

No. 12-5254 

UNITED STATES OF AMERICA, 
APPELLEE 

v. 

REGENERATIVE SCIENCES, LLC, A CORPORATION, ET AL., 
APPELLANTS 

Appeal from the United States District Court 
for the District of Columbia 
(No. 1:10-cv-01327) 

It has been an interesting ride.  Chris Centeno and his partners (and investors) have been the lightning rod for a lobby and debate around the right way to regulate the use of cells therapeutically - particularly one's one cells.  The arguments became more sophisticated as the case wore on and, as so often happens, the ground shifted considerably while the case was ongoing.  The case and Chris Centeno's unparalleled commitment to the cause has contributed significantly to a debate that is important to have and I suspect is not over simply because the case is done.

Dr. Centeno and I have had our differences but now is the time to recognize his contributions to the debate and, more importantly, to the field. We look forward to his future contributions to developing robust, cell-based treatments for patients.